Multimodality treatment for sinonasal neuroendocrine carcinoma

Mitchell, Elisabeth H.; Díaz, Álvaro; Yilmaz, Türker; Roberts, Dianna B.; Levine, Nicholas B.; DeMonte, Franco; Hanna, Ehab Y.; Kupferman, Michael E.

doi:10.1002/hed.21940

Cited by 74 publications

(81 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the lack of a consensual therapeutic modality, the multimodality approach (chemo and radiotherapy) showed evidence of increment in the survival rate of patients with the diagnosis of sinonasal small cell neuroendocrine carcinoma 20 , 21. In our case, the option of sequential treatment (chemo followed by radiotherapy) was based on the histology type and the tumor size.…”

Section: Resultsmentioning

confidence: 63%

Small cell neuroendocrine carcinoma of the nasopharynx: a rare case report

Azevedo

Rios

Vendeira

et al. 2017

ACR

View full text Add to dashboard Cite

Small cell neuroendocrine carcinoma rarely appears primarily in the head and neck and exhibits aggressive behavior with a poor prognosis. The pathologist has a significant role in the diagnosis, and a consensual treatment still does not exist. The authors report the case of a middle-aged male patient who presented repeated episodes of massive epistaxis. The diagnostic work-up disclosed the diagnosis of small cell neuroendocrine carcinoma of the nasopharynx. The patient was treated with chemotherapy followed by radiotherapy. Imaging examinations performed after the end of treatment showed apparent complete remission of the disease. The patient was kept under active surveillance with no signs of local relapse or distant metastasis after 4 years of follow-up.

show abstract

Section: Resultsmentioning

confidence: 63%

Small cell neuroendocrine carcinoma of the nasopharynx: a rare case report

Azevedo

Rios

Vendeira

et al. 2017

ACR

View full text Add to dashboard Cite

show abstract

“…However, the sphenoid sinuses are sited at the central part of the skull base and adjacent to several important neurovascular structures. Therefore, an R0 resection for local advanced carcinoma of the sphenoid sinuses is rather a challenge for the surgeon [1]. In our case, only an R2 resection could be done as the tumor cells had invaded the optic nerve.…”

Section: Discussionmentioning

confidence: 90%

“…Located at the critical region contiguous with the central nervous system, sphenoidal carcinomas pose a particular challenge to complete resection of the tumor [1]. Moreover, the use of radiotherapy and/or chemotherapy is controversial as they have little effect on survival of patients in advanced disease [2].…”

Section: Introductionmentioning

confidence: 99%

Successful Management of Recurrent Neuroendocrine Carcinoma of the Sphenoid Sinus Using Octreotide LAR: A Case Report

Liuyiqian¹,

Caixiaomin²,

Zhuweiyou³

et al. 2017

J Carcinog Mutagen

View full text Add to dashboard Cite

Overexpression of somatostatin (SST) receptors detected in most neuroendocrine carcinomas (NECs) appears to play an important role in the pathogenesis of NECs. Inhibition of SST receptors with SST analogues has been proved to be effective in various types of neuroendocrine tumors. We present here a case report of a 59-year-old female with recurrent sphenoidal NEC treated with SST analogues Octreotide and Octreotide long-acting release (LAR) as a salvage therapy. Improvement of optic nerve compression and quality of life (QOL) were observed along with a 77 months of progression free survival. This result suggests that OCT/OCT LAR may be a new approach to treating advanced NECs of the paranasal sinuses.

show abstract

“…Owing to the rarity of NETs, these treatment modalities have not been systematically evaluated 7. Surgery is usually reserved for cases where complete tumour resection can be achieved with minimal morbidity or when the tumour is not responsive to chemoradiation 11 15 16…”

Section: Discussionmentioning

confidence: 99%

Diagnosis and treatment of a rare sinonasal neuroendocrine tumour: adding to the evidence

et al. 2016

View full text Add to dashboard Cite

Sinonasal neuroendocrine tumours (NETs) are rare, aggressive neoplasms with a high recurrence potential. There are no robust protocols for the management of these tumours. An 81-year-old man presented with an incidental sinonasal mass visualised on CT scan of head. Over the next few weeks he developed new onset, progressively worsening headache, right eye ptosis and restricted extraocular movements. Imaging confirmed a rapidly enlarging tumour involving the right nasal cavity and the orbit. Biopsy showed a large cell neuroendocrine carcinoma of the right ethmoidal sinus. The patient was treated with concurrent cisplatin chemotherapy and radiation. Repeat imaging showed decrease in tumour volume. The patient continues to do well and follows up regularly with our oncology service. Current protocols comprising chemotherapy after radiation are based on limited studies. A regimen involving concurrent chemoradiation also appears to aid in tumour volume reduction. Additional studies are required to formulate robust clinical protocols for management of sinonasal NETs.

show abstract

Multimodality treatment for sinonasal neuroendocrine carcinoma

Abstract: NEC of the paranasal sinuses is an exceedingly rare malignancy of the paranasal sinuses. Our data suggests definitive management with surgery or radiotherapy offers durable control. The response to chemotherapy may predict for overall outcomes.

Cited by 74 publications

References 14 publications

Small cell neuroendocrine carcinoma of the nasopharynx: a rare case report

Small cell neuroendocrine carcinoma of the nasopharynx: a rare case report

Successful Management of Recurrent Neuroendocrine Carcinoma of the Sphenoid Sinus Using Octreotide LAR: A Case Report

Diagnosis and treatment of a rare sinonasal neuroendocrine tumour: adding to the evidence

Contact Info

Product

Resources

About